CLINICAL_TRIALS
trial_result
· 2012-09-06
Clinical Trial Update: Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma [Phase 2]
Summary
A Phase 2 study of cediranib in metastatic or recurrent renal cell carcinoma has completed, with results posted in 2012.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: AstraZeneca | Conditions: Renal Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2012-09-06